ArticleFrontiers in oncology2026
Development of multi-algorithm machine learning models integrating novel serum biomarkers for survival prediction in colorectal cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) prognosis prediction remains challenging due to tumor heterogeneity, and existing machine learning-based prognostic studies often rely on single algorithms or limited feature types. This study aims to employ a multi-algorithm collaborative strategy to identify critical prognostic factors for CRC patients and develop integrated prognostic nomograms that combine multi-dimensional features. Methods: Deep machine learning analysis was conducted in the R environment using the randomForest, glmnet (for LASSO regression), and caret packages. Three algorithms (LASSO regression, XGBoost, Random Forest) were applied to screen 73 clinicopathological features, with key hub features identified as the intersection of results from the three methods. Survival analysis was performed using the Kaplan-Meier method (log-rank test), and Cox regression analysis confirmed independent prognostic associations. Nomogram performance was validated via calibration curves, time-dependent AUC, C-index, decision curve analysis (DCA), and internal validation cohorts. Results: The multi-algorithm intersection identified 6 key hub features encompassing pathological (M stage, N stage), serological (Cystatin C, Homocysteine, γ-Glutamyl Transferase), and demographic (age) factors. Cox regression confirmed these as independent predictors of overall survival (OS) and progression-free survival (PFS) in CRC patients. Prognostic nomograms developed for 1-5 year OS and PFS showed excellent calibration (consistent predicted vs. observed survival) and high accuracy (OS C-index: 0.730, 95% CI: 0.707-0.753; PFS C-index: 0.722, 95% CI: 0.700-0.744; AUCs >75% for OS, >77% for PFS). DCA demonstrated superior clinical utility of the nomograms over traditional pathological staging. Internal validation cohorts confirmed robust predictive performance. Conclusions: Our study innovatively uses a multi-algorithm cross-validation strategy to identify 6 multi-dimensional hub features. It is the first to comprehensively integrate clinical, pathological, serological, and demographic factors into CRC prognostic nomograms, which outperform traditional staging and enable more personalized, clinically actionable prognosis prediction for CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.